-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 24, 2021, Cartesian Therapeutics announced that its investigational therapy Descartes-08 has achieved positive results in a phase 1b/2a clinical trial for patients with systemic myasthenia gravis (gMG)
.
Descartes-08 is an autologous chimeric antigen receptor T cell (CAR-T) therapy made by transforming T cells with mRNA, targeting B cell maturation antigen (BCMA)
Descartes-08 is a CAR-T therapy that uses mRNA to express CAR
.
Unlike current anti-B cell drugs, they target to eliminate pathogenic long-lived plasma cells that may survive in the body for decades, and are expected to prevent the production of autoantibodies for a long time
The press release pointed out that this non-randomized, single-group, open-label Phase 1b/2a trial is the first CAR-T cell therapy clinical trial for autoimmune diseases
.
The trial is planned to enroll 18 subjects to evaluate the safety and tolerability of Descartes-08 in the treatment of gMG
gMG is a chronic autoimmune disease.
The patient's autoantibodies will attack specific proteins at the neuromuscular junction, thereby destroying the way of communication between nerves and muscles, leading to muscle weakness and fatigue
.
People with gMG may experience various symptoms, from drooping eyelids and double vision, to debilitating muscle weakness and respiratory failure
▲The working principle of Cartesian's RNA Armory technology platform, which uses mRNA to express the target protein (picture source: Cartesian official website)
Reference materials:
[1] Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis.
(The original text has been deleted)
